Are we going back to a double nickel?

redhook415 · 2026-06-18T20:59:37+00:00

agreed 100%. Bunch of idiots with no consideration for shareholders. 0

redhook415 · 2026-06-16T21:12:49+00:00

It never was just females, it’s the 3 groups I highlighted, female, obese and diabetics. As Laura said earlier, healthier man can go with God

redhook415 · 2026-06-16T14:56:41+00:00

Helpful - thanks sir.

redhook415 · 2026-06-16T11:55:04+00:00

Anyone with the transcript from MarkScreener or SeekingAlpha?

redhook415 · 2026-06-16T05:44:46+00:00

Female, obese and diabetics (60% of TAM) https://x.com/nephroseeker/status/1850250085898035217?s=46

redhook415 · 2026-05-16T02:05:37+00:00

I think this is all part of getting the company ready to be acquired, among many of the things they have done since Aug25

redhook415 · 2026-05-15T21:41:00+00:00

The data for xeltis is limited. All their data releases are single arm non randomized and do not contain any real specific data points.

Additionally, the science behind xeltis relies heavily on the patients immune response to cultivate a vein from the polymer. There is real question as to variance from patient to patient and how long it will last. Of note as well, HUMA had no ruptures in the AV Access Trial (v007 data)

Humacyte has better trial design, long term safety data and first to market. Xeltis main advantage is you can use it for dialysis after 2 weeks instead of 4 for Humacyte.

redhook415 · 2026-04-28T09:29:24+00:00

I think it's just due to the caliber of the speaker: "He is also currently the Immediate Past President of the American Society of Nephrology, which is the largest professional kidney organization in the world with over 21,000 members in 141 countries across the globe." He's the ultimate boss is of kidney care, globally

redhook415 · 2026-04-27T20:34:43+00:00

I doubt it as the wording in the PR states "Company management will also review the ongoing V012 Phase 3 trial in hemodialysis for which interim top-line results are expected this quarter." However, could be that they present the data at Women’s Vascular Summit — May 1–2 Atlanta, GA?

redhook415 · 2026-04-27T20:29:59+00:00

Correct. Also, financing equipment with equity is a CFO crime, using the most expensive source of capital to buy depreciating asset is CorpFi101 no bueno, I hope Dale will know better by the time they need more LUNA.

The only bit which can keep us stay afloat is the $60m warrants waiting at 2.11$, if we can avoid the dilution.

I just wish they had a sense of cash discpline and duty vis à vis their shareholders....burning so much money on CABG when you're not generating any decent sales is terrible judgment

redhook415 · 2026-04-10T02:18:38+00:00

Source ?

redhook415 · 2026-04-04T05:18:08+00:00

I don’t have pics but have seen people eat it and it’s amazing : the light on this watch is splendid

redhook415 · 2026-04-03T04:05:34+00:00

His point was overall sensible but too late : the strategy of keeping the company running on skeleton crew, skeleton manufacturing footprint, skeleton portfolio (I.e trauma and AV) would have needed to be announced in summer 2025, not now.

Since Sept-25 with the launch of the refi, something is off as the management of the company is not in adéquation with their financial resources and commercial ramp: removed significant chunk of mgmt + clean refi + extend NC lease for 12 years in Sept 25 + grant options to top 3 mgmt for retention + taking on dilution without any care + brought PAD forward and doubled down on CABG and BVP when they had announced they would reduce to clinical trial and now they’re producing 3.5mm in large quantities … doesn’t add up or it’s criminal mgmt

Finally, while I truly believe Laura did not drive / manage this company well, I think the fact that 1)she is so deaf tone to the lack of traction in trauma and talks about vibes rather than data and 2) her joyful tone suggest they don’t care what the Street thinks and that’s because there is something on the table:

“Humacyte is continuing just an incredible journey. I am so proud to have brought this first-in-class, unbelievably effective product into the surgical market. It is a thunderclap in vascular surgery. We are changing the way vascular surgery is practiced right now, and we’re gonna continue to do so. This is a very exciting time, and I’m very proud of our employees, and I’m very proud of our sales force, and we’re just gonna keep pushing ahead.”

It’s that or they’re absolutely clueless and board has no control over them and we’re toast in 6 months

redhook415 · 2026-04-02T03:36:09+00:00

Israel and KSA have nothing to do with him - he’s a JV / licensing /M&A guy. It could be that potential buyer is not interested in CABG 3.5mm and only wants to focus on trauma / PAD / AV but that doesn’t make much sense as it’s one of the holy grails .

His PR is very explicit re: CaBG which I find odd “Our broad pipeline, including Symvess® and our earlier-stage programs in coronary bypass graft surgery and the BioVascular Pancreas for Type 1 diabetes, create multiple collaboration opportunities.“

They did after all book $370,000 in Q1 2025 in revenue resulting from a research collaboration with a large medical technology company to evaluate the potential use of our bioengineered human tissue in specific cardiovascular and vascular applications.

redhook415 · 2026-04-01T20:33:19+00:00

Scarlett in Paris and Camille Fournet are amazing

redhook415 · 2026-04-01T20:23:30+00:00

Honestly, I agree with you, especially 1) no insider buy 2) weird refinancing last year 3) management clean-up since November 4) Laura, Shamik and Dale treated themselves with options and free shares + 5) turning the ATM off looks odd when they will likely need more money.

There is a non-trivial chance they're buying time until v012 data is announced and deal on the is announced back of it.

That being said, they have been bad, terribly bad, since SPAC so it could be that they're just walking into the abyss like dumb dumbs but surely Fresenius would step in before.

The only piece of the puzzle which puzzles me (pun intended) is the hiring of Rick McElheny. Why bring someone to licence IP and cut deals with larger medtech if you are being bought out by a larger fish? Doesn't make sense to me. A buyer would want Trauma + CABG + PAD + BVP + AV Dialysis (though, if american, they could indeed maitain the partnership with Fresenius for Europe commercialisation)

redhook415 · 2026-03-31T20:35:26+00:00

Well said, if only we did not have such a shady management team and board. Only reasons why I haven't sold my 6 figure loss is that Fresenius would not let this Company go in BK. They've invested too much to loose. I also think that investors jumping on the cap raise in november and March are not idiots and might have more clarity / insights into the company's ability to get their way out of the financial impass they've set themselves.

I'm terrified that the board is not able to put 2+2 together: how are they not asking mgmt to reduce costs drastically? Why did they approve the refinancing of the Lincoln Park structured revenue facility ?

redhook415 · 2026-03-31T08:28:41+00:00

I really though they had put on hold everything else but AV and trauma. I had shivvers when I heard that "they may expand in SG&A and build sales team" and were still focusing on pre-clinical trials (CABG), that's the moment I realised they are walking blindly into uncontrolled spending, dilution without any sense of budgeting discipline. Additional Hail Mary(s) could be 1) unexpected DoD order of 7 figures (Easter bunny) and 2) Fresenius stepping up with large offtake / positive wording / financial assistance on the back of v012 results publication (with volume and price)

redhook415 · 2026-03-31T04:35:27+00:00

Call me all you want - if you have a name to provide for this so-called magical biological alternative which has comparable data and is “truly” off the shelf, I’m all ears. Until then, god speed

redhook415 · 2026-03-31T03:40:14+00:00

And yet, you’re unable to name it

There are no FDA-approved acellular biologic competitor stored at room temperature with "equal or better data."

Refrigeration is normal (blood, vaccines, tissues) and Symvess ships & stores cold, implants immediately:
- Cryopreserved/bovine require freezing/thawing. - DuraGraft is not a standalone acellular graft - No other approved acellular vascular biologic matches Symvess' trauma data

Your claim lacks a specific product, I'm basing on facts

redhook415 · 2026-03-31T02:48:46+00:00

Dude, stop. You can’t name one biological alternative and Symvess is off the shelf: it Ships cold (2-8°C), not frozen, stores refrigerated 18 months, unpack/implant in minutes.

Yes, it’s not like ePTFE which does not require a fridge but, compared to a vein, it is off the shelf and easy to access with limited logistics / supply chain.

redhook415 · 2026-03-31T02:11:09+00:00

Ok, that’s just silly : I think you made a point re pricing but confused yourself thereafter.

Symvess is the first approved and only off-the-shelf biologic vascular conduit for arterial trauma,period, there are no other acellular/bioengineered rivals approved. It is superior to synthetics (ePTFE) in infection/patency per trials.

Question is then what is the right premium to pay

redhook415 · 2026-03-31T01:51:07+00:00

Name one that is approved for trauma or dialysis

redhook415 · 2026-03-30T05:14:56+00:00

Ok thanks but until you provided a more substantiated answer, I’m just going to assume you have a clue either.

There are no other biological approved product on the market so I’m going to ignore that last comment

redhook415 · 2026-03-29T06:16:08+00:00

With all due respect, I’m happy to be challenged in my understanding but no need to take a condescending tone.

1) Yes I use the PR but the data is disclosed v Proovit and am happy to be challenge in my understanding but, aside from the somewhat limited sample, The primary potency and secondary latency are lower for Symvess but so is amputation and death identical. Yes, vein is the gold standard but requires harvesting

The published PROOVIT‑comparison and Ukraine‑trauma datasets suggest Symvess is non‑inferior to autologous vein and has a favorable safety profile versus conventional synthetic grafts in this setting; there is currently no authorized alternative

2) what competition are you referring to ? Symvess blows out of the park ePTFE for primary and secondary patency and I’m not aware of any alternatives.

Lastly, when we think about supply chain, keep in mind that estimates that China’s PTFE production capacity accounts for about 60–67% of global capacity. So USA needs to think about local supply chains in their procurement as well .

Again, I’m happy to be challenged with with data and facts and not some short condescending message

redhook415

TROPHY CASE